{
  "docId": "019de070-3b27-7318-9c92-a5817b78bd41",
  "docSlug": "ce86c4a3bf509aea21f24e2159890cb6",
  "documentTitle": "BioNTech | Results Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 28,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Slide 15 of a BioNTech presentation, referencing SITC 2018.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3b27-7318-9c92-a5817b78bd41/15",
  "deckHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41",
  "deckJsonHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41.json",
  "deckAnchorHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "chart",
      "text": "PDL1 Blockade and 41BB Agonism dose-response curves",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e12b715-6784-43b2-8984-ea6aad364ffb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Preclinical antitumor activity (tumor size over time)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2d8c401-d875-4379-83e1-b4d95815ee07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.47,
        "y": 0.028
      },
      "kind": "list",
      "text": "1. Evaluate safety, PK & mode of action; 2. Evaluate clinical activity in IO refractory/insensitive tumors",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f95438ce-f5b5-48c3-9ea2-aec640564f41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.48,
        "x": 0.47,
        "y": 0.052
      },
      "kind": "paragraph",
      "text": "Study design: First-in-human, open-label, dose-escalation trial... Enrollment: ~192 patients. First Data expected in 2H 2020",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fe8abf3-650a-4a9f-aba8-2fb86bd1702d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.5,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "*SITC 2018, Altintas et al",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bfe034b-fd16-4dc1-80d7-af61fa155ca6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT311 (anti-PDL1-anti-4-1BB)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbcdb0ce-7db5-4167-8f23-0cfcb91decf3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "9463e33d-5863-4956-82dd-79a6b9f164a2",
      "evidence": "list/numbered: 1. Evaluate safety, PK & mode of action; 2. Evaluate clinical activity in IO refractory/insensitive tumors",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "a7d0d755-e358-49e1-888b-58ab156af58d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation provides updates on the company's pipeline and progress in various trials",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "9d8a011b-49af-405a-9073-8a77c7487ff0",
      "evidence": "The presentation implies that not investing in innovative solutions could lead to missed opportunities",
      "position": 1,
      "objective": "What are the potential consequences of not investing in innovative solutions?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.5,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}